Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2008-12-31
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Unilateral Bevacizumab for Bilateral Diabetic Macular Edema
NCT00496405
Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)
NCT00406172
Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis
NCT01760746
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
NCT00336323
Bevacizumab as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
NCT01389505
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Panretinal Photocoagulation + Bevacizumab
Bevacizumab
Intravitreal administration
Group 2
Panretinal Photocoagulation
Panretinal Photocoagulation
Panretinal Photocoagulation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Intravitreal administration
Panretinal Photocoagulation
Panretinal Photocoagulation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BCVA of 20/63 or better (56 ETDRS letters
* No history of Macular Edema
* Central Retinal Thickness of 250mics or more
Exclusion Criteria
* Other ophthalmic diseases. history of Nephropathy, heart diseases and pregnancy
* Media opacities
15 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asociación para Evitar la Ceguera en México
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eduarto Torres-Porras, MD
Role: STUDY_DIRECTOR
Asociación para Evitar la Ceguera en México
Octavio Burgos, MD
Role: PRINCIPAL_INVESTIGATOR
Asociación para Evitar la Ceguera en México
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asociación para Evitar la Ceguera en México
Mexico City, Mexico City, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
APEC-035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.